Few people have been so integrally connected to surgery's various revolutions as Fred Moll, MD. Two decades ago Moll introduced one of the first enabling tools designed specifically for minimally invasive surgery, ushering in an age of surgery in closed spaces, before turning his attention in the 1990s to surgery's revolution-in-waiting, robotics, helping to launch the MIS revolution, In a recentinterview, Moll talks about those early days, what it was like for a young surgeon to build his first companies, and about the promise of robotics for the future of medicine.
by David Cassak
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
